Monte Rosa Therapeutics Inc share price logo

Monte Rosa Therapeutics Inc

NASDAQ: GLUE

Small Cap

$19.39

-0.18

(-0.92%)

Live

as on

Monte Rosa Therapeutics Inc Stock Performance

as on May 6, 2026 at 2:09 am IST

  • Day's Low

    Day's High

    $19.35
    $19.94
    downward going graph

    0.21%

    Downside

    2.84%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.51
    $25.77
    downward going graph

    81.90%

    Downside

    32.90%

    Upside

    downward going graph

Monte Rosa Therapeutics Inc share price movements today

Previous Close
$19.57
Open
$19.82
Volume
131.4K
Day's Low - High
$19.35 - $19.94
52 Week Low - High
$3.51 - $25.77

Monte Rosa Therapeutics Inc Historical Returns

1 Month Return
+ 14.51 %
3 Month Return
+ 3.54 %
1 Year Return
+ 322.68 %
3 Year Return
+ 277.8 %
5 Year Return
0 %

Monte Rosa Therapeutics Inc Stock Fundamentals & Key Indicators

Check Monte Rosa Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.5B

EPS (TTM)

-1.521

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-45.9M

Revenue (TTM)

123.7M

Profit Margin

-31.23%

Return On Equity TTM

-16.94%

Monte Rosa Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Monte Rosa Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Monte Rosa Therapeutics Inc image
Monte Rosa Therapeutics Inc
BUY$1.5BNANA-31.23%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.8B124.56%74.6712.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$109.3B100.99%27.732.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$33.0BNA118.865.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$73.5B47.01%17.1229.65%

Stock Returns calculator for Monte Rosa Therapeutics Inc Stock including INR - Dollar returns

The Monte Rosa Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Monte Rosa Therapeutics Inc investment value today

Current value as on today

₹4,73,368

Returns

₹3,73,368

(+373.37%)

Returns from Monte Rosa Therapeutics Inc Stock

₹3,18,790 (+318.79%)

Dollar Impact

₹54,578 (+54.58%)

Analyst Recommendation on Monte Rosa Therapeutics Inc Stock

Based on 14 analysts

BUY

92.86%

Buy

7.14%

Hold

0.00%

Sell

Based on 14 analysts, 92.86% of analysts recommend a 'BUY' rating for Monte Rosa Therapeutics Inc. Average target price of $32.17

Monte Rosa Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Monte Rosa Therapeutics Inc.

What analysts predicted

39.73%UPSIDE

Target Price

$32.17

Current Price

$19.39

Analyzed by

14 Analysts

Target

$32.17

Monte Rosa Therapeutics Inc target price $32.17, a slight upside of 39.73% compared to current price of $19.39. According to 14 analysts rating.

Monte Rosa Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Monte Rosa Therapeutics Inc Stock has increased by 96% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:96% versus previous 30 day period

Monte Rosa Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
8
1
4
9
60
84
23
12
2
Gross Profit
-1
-1
0
2
9
60
84
23
10
0
Operating Income
-36
-34
-34
-32
-26
13
44
-15
-32
-49
EBITDA
-35
-33
-33
-30
-24
15
46
-13
-28
-47
Interest Expense
-
0
-
-
-
-
-
-
-
-
Depreciation
1
1
1
2
2
2
2
2
2
2
Income Before Tax
-34
-33
-31
-30
-23
15
47
-11
-30
-46
Income Tax Expense
0
0
0
0
0
2
0
1
-3
0
Net Income
-34
-33
-31
-30
-23
13
46
-12
-27
-46
Net Profit Margin
0.00%
-379.94%
-3004.51%
-645.58%
-258.89%
22.16%
55.20%
-53.01%
-212.10%
-1658.94%

Monte Rosa Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
75
123
Gross Profit
0
0
-2
-8
-6
67
115
Operating Income
-7
-28
-72
-112
-143
-81
-54
EBITDA
-7
-27
-70
-108
-137
-72
-45
Interest Expense
0
0
1
3
-
-
-
Depreciation
0
0
2
3
5
8
8
Income Before Tax
-7
-35
-73
-108
-135
-70
-39
Income Tax Expense
0
0
-2
-3
0
2
-1
Net Income
-8
-35
-73
-108
-135
-72
-38
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
-96.14%
-31.23%

Monte Rosa Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-33
-31
-30
-23
13
46
-12
-27
-46
Operating Cash Flow
29
-38
-27
-20
128
-45
-34
100
-43
Investing Cash Flow
14
9
-61
37
-30
-100
25
38
-65
Financing Cash Flow
25
0
98
0
0
0
0
0
29
Change in Cash
69
-28
9
16
98
-145
-9
138
-78

Monte Rosa Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-35
-73
-108
-135
-72
-38
Operating Cash Flow
-23
-59
-92
-43
41
-22
Investing Cash Flow
-3
-9
-219
88
-44
-101
Financing Cash Flow
60
377
20
27
98
30
Change in Cash
32
308
-291
72
96
-94

Global Institutional Holdings in Monte Rosa Therapeutics Inc

Funds
Holdings
Alphabet Inc
1.83%
BRAIDWELL LP
1.19%
Vestal Point Capital LP
0.97%
NEA Management Company, LLC
9.61%
Geode Capital Management, LLC
1.51%
See all

Monte Rosa Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 15 September

    Mon, 08:59 PM

    -

    Monte Rosa announces collaboration with Novartis for novel degraders, receiving $120 million upfront and potential total payments of $5.7 billion.

Insights on Monte Rosa Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, GLUE stock has moved up by 59.0%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, GLUE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GLUE has outperformed top 5 stocks with highest market-cap in its industry

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
OrganisationMonte Rosa Therapeutics Inc
Headquarters321 Harrison Avenue, Boston, MA, United States, 02118
IndustryBiotechnology
CEOMr. Philip Nickson J.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Monte Rosa Therapeutics Inc

Name

Title

Mr. Andrew Funderburk

Chief Investor Relations and Strategy Officer

Mr. Philip Nickson J.D., Ph.D.

Chief Business & Legal Officer

Mr. Filip Janku M.D., Ph.D.

Chief Medical Officer

Mr. Matthew Bowen

Corporate Controller & Principal Accounting Officer

Ms. Jennifer Champoux

Chief Operating Officer

Mr. Magnus Walter DPHIL

Chief Technology Officer

Dr. John C. Castle Ph.D.

Chief Data & Information Officer

Dr. Sharon Townson Ph.D.

Chief Scientific Officer

FAQs

What is Monte Rosa Therapeutics Inc share price today?

Monte Rosa Therapeutics Inc share price today is $19.39 as on . Monte Rosa Therapeutics Inc share today touched a day high of $19.94 and a low of $19.35.

What is the 52 week high and 52 week low for Monte Rosa Therapeutics Inc share?

Monte Rosa Therapeutics Inc share touched a 52 week high of $25.77 on and a 52 week low of $3.51 on . Monte Rosa Therapeutics Inc stock price today i.e. is trending at $19.39,which is 24.76% down from its 52 week high and 452.42% up from its 52 week low.

What is Monte Rosa Therapeutics Inc's market capitalisation today?

Monte Rosa Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Monte Rosa Therapeutics Inc Stock (GLUE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Monte Rosa Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Monte Rosa Therapeutics Inc Shares that will get you 0.0774 shares as per Monte Rosa Therapeutics Inc share price of $19.39 per share as on May 5, 2026 at 8:39 pm IST.

What is the minimum amount required to buy Monte Rosa Therapeutics Inc Stock (GLUE) from India?

Indian investors can start investing in Monte Rosa Therapeutics Inc (GLUE) shares with as little as ₹95.28 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.80 in Monte Rosa Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Monte Rosa Therapeutics Inc share’s latest price of $19.39 as on May 5, 2026 at 8:39 pm IST, you will get 0.5157 shares of Monte Rosa Therapeutics Inc. Learn more about fractional shares .